comparemela.com

Latest Breaking News On - Rene braeckman - Page 1 : comparemela.com

IH Drug Candidate Tolerated Across Doses, Interim Data Shows

Interim data from a phase 2 trial of KP1077 in patients with IH indicates the drug is well-tolerated at all tested doses and dosing schedules.

Rene braeckmanZevra therapeutic

Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNichol ochsnerJanine bogrisRene braeckmanUs drug enforcement agencyClinical developmentExchange commissionZevra therapeutics incDrug administrationSenior vice presidentEpworth sleepiness scalePatient global impressionClinical global impressionIdiopathic hypersomnia severity scaleIdiopathic hypersomniaOrphan drug designation

KP1077 Rivals Ritalin in Heart Safety for Idiopathic Hypersomnia

Zevra Therapeutics highlighted the heart safety of SDX, the main ingredient in KP1077, its potential treatment for idiopathic hypersomnia.

Rene braeckmanPsych congressZevra therapeutics

Zevra Therapeutics Presents Full Data Set on the

CELEBRATION, Fla., Sept. 09, 2023 (GLOBE NEWSWIRE) Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics.

United statesJennifer arcureRene braeckmanNichol ochsnerPsych congress poster award reception onUs drug enforcement agencyCorium incClinical development at zevraPsych congressZevra therapeutics incClinical developmentDrug administrationExchange commissionVice presidentPsych congress poster award receptionSingle dose crossover study

Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and Pharmacokinetics of SDX, the sole API in KP1077, in Healthy Volunteers at Psych Congress 2023

CELEBRATION, Fla., Sept. 09, 2023 Zevra Therapeutics, Inc. , a rare disease therapeutics company, today announced a poster presentation featuring study data that underscores the cardiovascular.

United statesNichol ochsnerRene braeckmanJennifer arcureUs drug enforcement agencyCorium incDrug administrationZevra therapeutics incClinical developmentExchange commissionPsych congress poster award receptionGlobenewswire incPsych congressClinical development at zevraVice presidentSingle dose crossover study

vimarsana © 2020. All Rights Reserved.